GEDULD E E has current investment portfolio of $141 million as per its recent SEC 13F filing on October 30 with Bank of America Corp (NYSE:BAC), Morphosys Ag (ADR) (OTCMKTS:MPSYY), Johnson & Johnson (NYSE:JNJ) as its primary stock holdings. GEDULD E E has its primary investments in finance and healthcare industry.
Bank of America Corp (NYSE:BAC) is the largest stock holding of GEDULD E E, which owns 2,524,548 shares of the bank at market value of $43 million. Bank of America Corp (NYSE:BAC) reported its third quarter 2014 financial results with net revenues of $21.4 billion and net income of $168 million for the quarter. Fairholme, Fisher Asset Management, and Pzena Investment Management are among the primary investors of Bank of America Corp (NYSE:BAC).
Morphosys Ag (ADR) (OTCMKTS:MPSYY) comes at number two in the portfolio of GEDULD E E with 55,000 shares of the company at net market value of $5.39 million. Earlier this quarter, Morphosys Ag (ADR) (OTCMKTS:MPSYY) acquired lanthipeptide technology from Lanthio Pharma. The company has net market capitalization of $2.57 billion and its shares are trading at current price of $49.22.
Johnson & Johnson (NYSE:JNJ) is the third largest stock investment of GEDULD E E, which owns 25,000 shares of the company with current market value of $2.66 million. The shares of Johnson & Johnson (NYSE:JNJ) have increased 17% year-to-date with current share price of $107.21 and the company has current market capitalization exceeding $300 billion.
Johnson & Johnson (NYSE:JNJ) entered into a partnership with Geron Corporation (NASDAQ:GERN) for the experimental blood cancer treatment drug of the company. Johnson & Johnson has already paid $35 million for the drug while it is in the early stages and if the drug receives approval and achieves its commercial goals, the company will pay additional $900 million to Geron Corporation (NASDAQ:GERN).
This article has been written by Prakash Pandey.
Genetically Modified Organisms Examples